Spark Investment Management LLC increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 18.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 88,200 shares of the medical research company’s stock after buying an additional 13,500 shares during the period. Spark Investment Management LLC owned approximately 0.19% of Charles River Laboratories International worth $8,921,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Envestnet Asset Management Inc. increased its stake in shares of Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock worth $135,000 after buying an additional 526 shares during the last quarter. Cambridge Advisors Inc. bought a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $202,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $217,000. MAI Capital Management bought a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $224,000. Finally, Massmutual Trust Co. FSB ADV increased its stake in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock worth $246,000 after buying an additional 130 shares during the last quarter. Hedge funds and other institutional investors own 95.81% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (CRL) traded up 1.29% on Friday, reaching $97.97. The company had a trading volume of 499,107 shares. The firm has a 50-day moving average price of $99.80 and a 200 day moving average price of $91.67. Charles River Laboratories International, Inc. has a 1-year low of $67.20 and a 1-year high of $102.32. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of 25.82 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. Charles River Laboratories International’s revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.20 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has authorized a share repurchase program on Wednesday, May 10th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: This piece was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://theolympiareport.com/2017/08/12/spark-investment-management-llc-boosts-position-in-charles-river-laboratories-international-inc-crl-updated.html.

A number of analysts have recently commented on the company. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a research note on Thursday. Barclays PLC set a $90.00 price target on Charles River Laboratories International and gave the stock a “hold” rating in a report on Saturday, May 13th. Jefferies Group LLC reissued a “buy” rating and set a $121.00 target price on shares of Charles River Laboratories International in a report on Friday, June 30th. Credit Suisse Group reissued a “neutral” rating and set a $95.00 target price (up previously from $89.00) on shares of Charles River Laboratories International in a report on Tuesday, June 6th. Finally, BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $96.94.

In other news, Chairman James C. Foster sold 43,154 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the completion of the sale, the chairman now directly owns 361,178 shares in the company, valued at approximately $36,117,800. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Davide Molho sold 10,976 shares of the company’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $92.84, for a total value of $1,019,011.84. Following the sale, the insider now owns 27,525 shares of the company’s stock, valued at $2,555,421. The disclosure for this sale can be found here. Insiders sold a total of 79,369 shares of company stock valued at $7,846,412 over the last quarter. 2.20% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.